💊 #FDA Approval Update | #Libtayo (#cemiplimab-rwlc) as the adjuvant treatment of high-risk #CSCC
⬇️Supported by the Phase 3 C-POST trial
✔️Reduced the risk of recurrence or death by 68% compared with placebo
🌟MedChemExpress provides Cemiplimab for research use.
🔗Read more at fda.gov
#PD-1 #cemiplimab

Regeneron's Libtayo stakes out new territory in skin cancer Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

#Regeneron #Libtayo #cemiplimab #skincancer #Squamouscellcarcinoma #checkpointinhibitor #FDA #cutaneoussquamouscellcarcinoma #CSCC #basalcellcarcinoma #nonsmallcelllungcancer #cervicalcancer #highriskCSCC #KEYNOTE630study #CPOSTstudy #Libtayotreatedpatients #PD1PDL1inhibitors
zurl.co/9toKK

Oncology Weekly News – September 15th 2025 Oncology Update : Ozuriftamab Phase 3, Libtayo 5-Year Data, INLEXZO Approval and More From FDA-aligned Phase 3 designs and AI-driven […] The post Oncology Weekly News – September 15th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Oncology Weekly News – September 15th 2025 #News #BioNTech #Libtayo #Cemiplimab #OvarianCancer Comment below!

Cemiplimab-rwlc (Libtayo) Updates 2025: Uses in cancer, Side effects, Dosage, Expectations and more - OncoDaily This article is about Cemiplimab-rwlc (Libtayo), its uses, side effects, dosage, and what to expect during treatment.

Cemiplimab-rwlc (Libtayo) Updates 2025: Uses in cancer, Side effects, Dosage, Expectations and more

oncodaily.com/drugs/cemipl...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Cemiplimabrwlc #Libtayo

ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.

#Regeneron's PD-1 inhibitor #Libtayo could find wider use for a form of #skincancer known as #cutaneoussquamouscellcarcinoma after showing efficacy in a pivotal trial as adjuvant therapy for patients who have had surgery to remove their tumour.

pharmaphorum.com/news/asco-25...

Libtayo available in Scotland for cervical cancer patients - PharmaTimes New immunotherapy offers hope for recurrent cervical cancer

#oncology #womenshealth #Libtayo #cemiplimab #NHSScotland #cervicalcancer #immunotherapy #Regeneron #ScottishMedicinesConsortium #SMCacceptance #SMC #metastaticcervicalcancer #humanmonoclonalantibody #immunecheckpointreceptor #EMPOWERCervical1phase3trial
pharmatimes.com/news/libtayo...